The clock starts before a medicine reaches patients
A drug patent’s term is generally counted from the date the patent application is filed, not from the date the medicine is approved or first sold. That application may be filed while a candidate drug is still being tested. Years of laboratory work, clinical trials in people, and regulatory review can follow—but the original patent’s clock keeps running throughout.
That timing creates a costly tradeoff. Filing early can help protect an invention before others copy it, but it also means the company may spend much of the patent term proving that the drug is safe and effective. By the time sales begin, the company may have fewer protected years in which to recoup research and development costs.
What protection does—and doesn’t—guarantee
A patent gives its owner the right to prevent others from making, using, or selling the invention it covers, subject to the patent’s scope and applicable law. It does not automatically make a drug the only treatment available, nor does every patent on a medicine expire on the same day. A drug can be covered by patents on different features, such as its active ingredient or a particular formulation; those protections have their own terms and may not all be equally important.
When relevant patent barriers end, generic manufacturers may be able to seek approval to sell equivalent versions. The transition is not always immediate: regulatory requirements and other legal protections can still matter. But the filing-date clock explains why a medicine’s commercial life under its earliest patent can be much shorter than twenty years after launch.
